Published in Drug Week, February 13th, 2004
CTCL "is classified as an indolent hematologic malignancy with distinct clinicopathologic features," oncologists in Chicago explained. "Although prognosis varies depending on the stage, patients who have cutaneous tumor, lymph node or visceral involvement, or peripheral blood involvement (Sezary syndrome) generally have a poor outcome."
"In one report, patients with tumor stage, erythroderma, or peripheral blood involvement had a median survival of 40 months; patients who had visceral involvement had a median...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.